Optamont (Olopatadine)

Olopatadine blocks histamine H1 receptors on mast cells and other cells in the eye and nasal mucosa, preventing histamine‑induced inflammation. It also stabilises mast cells, reducing the release of additional inflammatory mediators, which together diminish allergic symptoms.

The dosage of Optamont is determined by the prescribing clinician based on the patient’s age, severity of symptoms, and formulation strength. Patients should follow the specific instructions provided by their healthcare professional and the product label.

Safety data for olopatadine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To request Optamont, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Optamont’s olopatadine combines H1‑receptor antagonism with mast‑cell stabilisation, offering both rapid symptom relief and longer‑term control. Compared with older antihistamine drops that lack mast‑cell stabilising activity, Optamont may provide more consistent relief of itching and reduced recurrence of inflammation.

Optamont should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct light. Do not freeze the product. Keep the container tightly closed when not in use and discard any solution that appears discoloured or contaminated.

Optamont is applied as eye drops. The patient should wash hands, tilt the head back, pull down the lower eyelid, and instil the prescribed number of drops into the conjunctival sac. The eye should be closed gently for a few seconds to allow even distribution.

While rare, serious adverse events can include severe allergic reactions such as anaphylaxis, corneal ulceration, or a significant rise in intra‑ocular pressure. Patients should seek immediate medical attention if they experience swelling of the face or throat, intense eye pain, or sudden vision changes.

Optamont should be avoided in individuals with a known hypersensitivity to olopatadine or any of its excipients. It is also contraindicated in patients who have experienced severe ocular reactions to other antihistamine eye drops and in those for whom a prescription antihistamine is medically inappropriate.